Recombinant Human VEGFR2/KDR Fc His Alexa Fluor® 647 Protein

Catalog #: AFR357 Datasheet

Catalog #	Availability	Size / Price	Qty
AFR357-020

Detection of Human VEGFR2/KDR/Flk-1 Antibody with Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera His-tag Alexa Fluor® 647 Protein by Flow Cytometry.

2 Images

All VEGFR2/KDR/Flk-1 Proteins and Enzymes

Product Details

FAQs

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGFR2/KDR Fc His Alexa Fluor® 647 Protein Summary

Learn more about Fluorokines^TM Fluorescent-Labeled Proteins

Product Specifications

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

Activity

Measured by flow cytometry for its ability to bind Human VEGFR2/KDR/Flk-1 Antibody conjugated fluorescent beads at 2.50-10.0 µg/mL (100 µL/well).
Please Note: Optimal dilutions should be determined by each laboratory for each application.

Source

Mouse myeloma cell line, NS0-derived human VEGFR2/KDR/Flk-1 protein

Human VEGFR2 (Ala20-Glu764) Accession # AAC16450.1	IEGRMD	Human IgG₁ (Pro100-Lys330)	6-His tag
N-terminus			C-terminus

Accession #

AAC16450.1

N-terminal Sequence
Analysis

Ala20

Structure / Form

Disulfide-linked homodimer

Labeled with Alexa Fluor® 647

Excitation Wavelength: 650 nm

Emission Wavelength: 668 nm

Predicted Molecular Mass

110 kDa (monomer)

SDS-PAGE

150-170 kDa, under reducing conditions.

Product Datasheets

AFR357

Product Datasheet

AFR357

Formulation	Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Shipping	The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after opening. 3 months, -20 to -70 °C under sterile conditions after opening.

Scientific Data

Flow Cytometry

View Larger

Fluorescent beads conjugated to Human VEGFR2/KDR/Flk-1 Antibody were stained with (A) Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera His-tag Alexa Fluor® 647 (Catalog # AFR357, filled histogram) or (B) unstained (open histogram).

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human VEGFR2/KDR Fc His Alexa Fluor® 647 Protein (Catalog # AFR357) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 150-170 kDa and 300-340 kDa, respectively.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References

Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Alternate Names

CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

Product Specific Notices

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.